Immunic, Inc.
NASDAQ:IMUXBiotechnology
-$0.04 today
- Market cap
- $102.61M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
Volume 0.17M
Average 0.27M
IMUX Account Payables
Amounts the company owes suppliers for goods and services received.
Immunic, Inc.NASDAQ: IMUX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 90.9% from a year ago
Account payables stood at $10.51M at the end of Q1 FY2026, up 90.9% from a year earlier and up 3.7% from the prior quarter. Over 3 fiscal years it compounded at +33.3% a year.
Context
- Account payables amounted to 5.5% of total assets at the end of Q1 FY2026, down 21.3 pp from a year earlier.
- Account payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +90.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 10.14M USD
- Year-over-year change
- +29.2%
- 4-year CAGR
- +30.5%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.14M | +29.2% |
| FY2024 | 2024-12-31 | 7.85M | +53.9% |
| FY2023 | 2023-12-31 | 5.1M | +19.1% |
| FY2022 | 2022-12-31 | 4.28M | +22.3% |
| FY2021 | 2021-12-31 | 3.5M | — |
Account Payables vs competitors
How IMUX compares with its peers on the latest reported figures
- IMUX's Mar 2026 account payables of $10.51M is the 2nd highest of the 9 companies compared; the peer median is $3.77M.
- Its year-over-year change of +90.9% is the 2nd highest of 9, against a peer median of -36.8%.
- Account payables amounts to 5.5% of total assets for IMUX, versus a peer median of 1.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $24.19M | +45.5% | +57.4% | 13.4% | |
| Mar 2026 | $10.51M | +90.9% | +33.3% | 5.5% | |
| Mar 2026 | $5.73M | +353.1% | -33.2% | 2.4% | |
CBUSCibus, Inc. | Mar 2026 | $5.41M | -20.2% | +187.4% | 1.7% |
| Mar 2026 | $4.61M | -40.1% | -22.1% | 9.9% | |
| Mar 2026 | $2.93M | -33.5% | +2.5% | 1.7% | |
| Mar 2026 | $2.3M | -53.6% | -24.7% | 1.1% | |
| Mar 2026 | $1.63M | -54.6% | +1.7% | 1.7% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $1.16M | -68.5% | +36.1% | 1.1% |
| Peer median (excluding IMUX) | $3.77M | -36.8% | +2.1% | 1.7% | |
Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 86.86M | 106.75M | 46.67M | 35.67M | 15.48M |
| Short-term Investments | 0 | 9.63M | 0 | 0 | 0 |
| Net Receivables | 2.15M | 296K | 703K | 684K | 4.12M |
| Inventory | 0 | 5.61M | 0 | 0 | 0 |
| Other Current Assets | 1.12M | 3.59M | 2.84M | 1.11M | 1.2M |
| Total Current Assets | 104.99M | 125.86M | 52.53M | 39.33M | 22.87M |
| Property, Plant & Equipment (Net) | 1.1M | 1.85M | 1.77M | 1.54M | 1.18M |
| Goodwill | 32.97M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 42K | 43K | 0 | 0 | 0 |
| Total Non-current Assets | 34.11M | 1.89M | 1.77M | 1.54M | 1.18M |
| Total Assets | 139.1M | 127.75M | 54.3M | 40.87M | 24.05M |
| Account Payables | 3.5M | 4.28M | 5.1M | 7.85M | 10.14M |
| Short-term Debt | 0 | 0 | 0 | 0 | 470K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 851K | 7.34M | 17.48M | 676K | 20.01M |
| Total Current Liabilities | 11.4M | 13.08M | 24.73M | 22.18M | 30.62M |
| Long-term Debt | 0 | 0 | 0 | 0 | 107K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | (107K) |
| Total Non-current Liabilities | 584K | 992K | 639K | 264K | 107K |
| Total Liabilities | 11.99M | 14.07M | 25.37M | 22.44M | 30.73M |
| Common Stock | 3K | 4K | 4K | 8K | 9K |
| Retained Earnings | (196.87M) | (317.28M) | (410.89M) | (511.4M) | (608.57M) |
| Accumulated OCI | (252K) | 3.04M | 3.76M | 4.21M | 2.65M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 127.12M | 113.68M | 28.93M | 18.43M | (6.67M) |
| Total Debt | 992K | 1.56M | 1.33M | 1M | 684K |
| Net Debt | (85.87M) | (105.18M) | (45.34M) | (34.66M) | (14.8M) |
Immunic, Inc.
NASDAQ:IMUX
Intrinsic Alpha fair value
Locked
Current Price
$7.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.